Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT06289504
- Locations
- 🇨🇦
Altasciences Company Inc., Mount-Royal, Quebec, Canada
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT06191991
- Locations
- 🇺🇸
PPD Austin Research Unit, Austin, Texas, United States
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 150
- Registration Number
- NCT06157099
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Statins in Patients With Spontaneous Intracerebral Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Pomeranian Medical University Szczecin
- Target Recruit Count
- 153
- Registration Number
- NCT06094244
- Locations
- 🇵🇱
Pomeranian Medical University, Szczecin, West Pomeranian, Poland
Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-12-21
- Target Recruit Count
- 80
- Registration Number
- NCT06080256
- Locations
- 🇨🇳
the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 50
- Registration Number
- NCT06052020
- Locations
- 🇨🇳
the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Systems Biological Assessment of Statin Effect on Vaccine Responses
- Conditions
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Emory University
- Target Recruit Count
- 86
- Registration Number
- NCT06024096
- Locations
- 🇺🇸
Hope Clinic, Atlanta, Georgia, United States
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05815680
- Locations
- 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China
Measuring Oncological Value of Exercise and Statin
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Tampere University Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05796973
- Locations
- 🇫🇮
Tampere University Hospital, Tampere, Länsi-Suomi, Finland
LDL-c Level Variability and Trained Immunity
- Conditions
- Interventions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 12
- Registration Number
- NCT05790499
- Locations
- 🇨🇳
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.